Eli Lilly Invests Weight-Loss Windfall in Next-Gen Cancer Treatment [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly is stocking its medicine cabinet with treatments that go beyond blockbuster GLP-1 drugs. On Monday, the pharma giant announced it'll buy blood cancer treatment-maker Kelonia Therapeutics in a deal worth as much as $7 billion. Lilly will pay about $3.3 billion up front under the terms of the agreement, expected to close in the back half of the year, and the rest if Kelonia hits specified regulatory and commercial milestones. Kelonia is developing a next-gen blood cancer treatment that reprograms T cells to help patients' immune systems fight cancer. The revolutionary aspect of Kelonia's treatment is that it'll reprogram its cells within the body. Current treatments extract cells, modify them outside the body, and then reintroduce them. Unlike current treatments, Kelonia's therapy won't require patients to undergo chemotherapy preemptively. Sign up for The Daily Upside at no cost for premium analysis on all your favorite stocks. READ ALSO: Blowout Earnings Reports Giv
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly's US$7b Kelonia Deal Reshapes Oncology And Valuation Story [Yahoo! Finance]Yahoo! Finance
- Eli Lilly eyes Kelonia in $7B deal with $3.25B to be paid up front before investors could buy in. How to get in early [Yahoo! Finance]Yahoo! Finance
- Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery [TheStreet.com]TheStreet.com
- Eli Lilly: We Haven't Reached Its Peak Yet (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Eli Lilly (LLY): 3 Reasons We Love This Stock [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 4/20/26 - Form SCHEDULE
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- LLY's page on the SEC website